

SHILPA PHARMA LIFESCIENCES LIMITED

Business Responsibility and Sustainability Report (BRSR, FY 22-23)

SECTION A: GENERAL DISCLOSURES

I. Details of the entity:

1. Corporate Identity Number (CIN): U24100KA2020PLC134081
2. Name of the Listed Entity: SHILPA PHARMA LIFESCIENCES LIMITED
3. Year of incorporation: 2020
4. Registered office address: #12-6-214/A-1, Shilpa House, Hyderabad Road, Raichur, Karnataka, India, 584135
5. Corporate address: #12-6-214/A-1, Shilpa House, Hyderabad Road, Raichur, Karnataka, India, 584135
6. E-mail: info@vbshilpa.com
7. Telephone: +91-8532-238704
8. Website: <https://www.vbshilpa.com/>
9. Financial year for which reporting is being done: 2022-23
10. Name of the Stock Exchange(s) where shares are listed: Not Applicable
11. Paid-up Capital: INR 10,00,00,000
12. Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report: Ms. Ritu Tiwary, Company Secretary, Email: cs@vbshilpa.com Contact Number: 08532 - 238704
13. Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together): The disclosure under this BRSR are on Standalone basis unless otherwise stated.

II. Products/services:

14. Details of business activities (*accounting for 90% of the turnover*):

S. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1	Manufacturing	Manufacturing of Active Pharmaceutical Ingredient (API)	100

15. Products/Services sold by the entity (*accounting for 90% of the entity's Turnover*):

S. No.	Product/Service	NIC Code	% of total turnover contributed
1	Active Pharmaceutical Ingredients	21001	100%

III. Operations:

16. Number of locations where plants and/or operations/offices of the entity are situated:

Location	Number of plants	Number of offices	Total
National	2	2	4
International	0	0	0

SHILPA PHARMA LIFESCIENCES LIMITED

17. Markets served by the entity:

a. Number of locations

Locations	Number
National (No. of States)	19
International (No. of Countries)	31

b. What is the contribution of exports as a percentage of the total turnover of the entity?

37.38%

c. A brief on types of customers

The company supplies its products to the manufacturers of Finished Pharmaceutical Formulations who will make the Pharmaceutical Formulations that is Drug Products.

IV. Employees:

18. Details as at the end of Financial Year

a. Employees and workers (including differently abled):

S.No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B/A)	No. (C)	% (C / A)
EMPLOYEES						
1.	Permanent (D)	1011	1009	99.80%	2	0.20%
2.	Other than Permanent (E)	0	0	0	0	0
3.	Total employees (D + E)	1011	1009	99.80%	2	0.20%
WORKERS						
4.	Permanent (F)	207	207	100%	0	0
5.	Other than Permanent (G)	419	419	100%	0	0
6.	Total workers (F + G)	626	626	100%	0	0

b. Differently abled Employees and workers:

S.No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B/A)	No. (C)	% (C / A)
DIFFERENTLY ABLED EMPLOYEES						
1.	Permanent (D)	3	3	100%	0	0
2.	Other than Permanent (E)	0	0	0	0	0
3.	Total employees (D + E)	3	3	100%	0	0
DIFFERENTLY ABLED WORKERS						
4.	Permanent (F)	1	1	100%	0	0

SHILPA PHARMA LIFESCIENCES LIMITED

S.No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B/A)	No. (C)	% (C / A)
5.	Other than Permanent (G)	0	0	0	0	0
6.	Total workers (F + G)	1	1	100%	0	0

19. Participation/Inclusion/Representation of women

Particulars	Total (A)	No. and percentage of Females	
		No. (B)	% (B / A)
Board of Directors	5	1	20%
Key Management Personnel	2	1	50%

20. Turnover rate for permanent employees and workers

Particulars	FY 22-23 (Turnover rate in current FY)			FY 21-22 (Turnover rate in previous FY)			FY 20-21 (Turnover rate in the year prior to the previous FY)		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	14.73%	0	14.73%	13.62%	0	13.62%	12.23%	0	12.23%
Permanent Workers	1.6%	0	1.6%	1.5%	0	1.5%	0.8%	0	0.8%

V. Holding, Subsidiary and Associate Companies (including joint ventures):

21. Names of holding / subsidiary / associate companies / joint ventures.

S.No.	Name of the holding/subsidiary/ associate companies/ joint ventures (A)	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by the entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the entity? (Yes/No)
1	Shilpa Medicare Limited	Holding company	100%	No
2	Shilpa Lifesciences Private Limited	Subsidiary Company	100%	No

VI. CSR Details:

22. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No)
(ii) Turnover (in INR) 615.61 Cr
(iii) Net worth (in INR) 17.8 Cr

SHILPA PHARMA LIFESCIENCES LIMITED

VII. Transparency and Disclosures Compliances

23. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No) (If Yes, then provide web-link for grievance redress policy)	FY 22-23 Current Financial Year			FY 21-22 Previous Financial Year		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Yes	0	0		0	0	
Investors (other than shareholders)	Yes	0	0		0	0	
Shareholders	Yes	0	0		0	00	
Employees and workers	Yes	3	0		1	0	
Customers	Yes	14	2	The resolution of these complaints is in progress	16	0	
Value Chain Partners	Yes	0	0		0	0	
Other (please specify)	-	-	-	-	-	-	-

Web link of the policy on grievance handling: -

<https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility2.pdf>

SHILPA PHARMA LIFESCIENCES LIMITED

24. Overview of the entity's material responsible business conduct issues

Indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, the rationale for identifying the same, approach to adapt or mitigate the risk along with its financial implications, as per the following format.

S No	Material Issue Identified	Risk / Opportunity	Rational for identifying risk or opportunity	In case of risk approach to adopt or mitigate	Financial implication of risk or opportunity
1	Availability of APIs and Affordability of Medicines (Social)	Opportunity	Sizeable number of patients with low-income level cannot afford to buy costly medicines. Our purpose "Innovating for Affordable Healthcare" drives us to improve access of affordable life-saving medicines for such patients worldwide.	NA	Positive
2	Sustainable Supply Chain (Social)	Risk	Our sustainable supply chain addresses the relevant environmental and social aspects of business, which are critical for the timely availability of our supplies and deliveries of our medicines to patients worldwide.	Implemented a process titled "Environmental & Social Assessments" of Suppliers	Negative
3	Energy & GHG (Environmental Sustainability)	Opportunity	Our environmental sustainability initiatives in the areas of energy conservation, energy efficiency, use of renewable energy, use of renewable fuels, water conservation, waste minimisation and green chemistry has positioned us to convert these environmental aspects to business opportunity. Reduce GHGs by using the renewable fuels, Project Registered with UNFCC for GHS gasses reduction & earning the CER's. The Company Earns Carbon Credits from the UNFCC (Tradable) from its Biomass fuel based Steam generation project. Energy costs reduction by energy (Electrical and	NA	Positive

SHILPA PHARMA LIFESCIENCES LIMITED

S No	Material Issue Identified	Risk / Opportunity	Rational for identifying risk or opportunity	In case of risk approach to adopt or mitigate	Financial implication of risk or opportunity
			Thermal) conservation measures The Energy conservation measures are taken up continuously. Resource usage reduction, water recycling.		
4	Health & Safety of employees, visitors, and neighbouring communities (Occupational Health & Safety)	Risk	Safe working environment boosts the employee & other stakeholders' satisfaction & confidence resulting in consistent and uninterrupted operations. We consider health and safety of employees, visitors, and neighbouring communities as our priority. They are key stakeholders of our responsible business operations, and we are committed to provide them a healthy and safe environment. Also, Health & Safety incidents involve significant financial, legal and moral costs, which affects business continuity. Risk of failure / non-compliance can adversely impact our business operations and in-turn patient needs.	Mitigate Implemented "Occupational Health & Safety Management System" and "Process Safety Management System".	Negative
5	Promotion of Diversity (Social)	Risk	We consider diversity as an important aspect for our organisation as it brings new innovative ideas for continual improvement and long-term value creation for our stakeholders. We continuously strive to provide an inclusive work culture to our employees.	Mitigation Implemented "Social Accountability Management System".	Negative
6	Business Interruption due to Supply Chain Interruptions	Opportunity	1) Backward integration of the intermediates. 2) Sourcing of Materials & services by sustainable practices. Results in the uninterrupted business continuity and	NA	Positive

SHILPA PHARMA LIFESCIENCES LIMITED

S No	Material Issue Identified	Risk / Opportunity	Rational for identifying risk or opportunity	In case of risk approach to adopt or mitigate	Financial implication of risk or opportunity
			ensures the customer satisfaction		
7	Sustainable EHS work practices (EHS)	Opportunity	<p>Company has adopted and made the sustainable practices as its culture. All personnel participate in the sustainable practices with focus on energy conservation, emission control, waste minimisation, resource reduction, preventive maintenance, hazard identification & risk assessment activity based, safe operating procedures, hazard & operability studies. 24 Hrs monitoring by the Safety Co-ordinators, GMP Co-ordinators, Night Shift Officers and Duty Managers for each production block. The waste Treatment with Zero Discharge Facility, The Treated water from the ZLD is Recycled.</p>	NA	Positive
8	Ensuring No Discrimination and No Harassment (Social)	Risk	<p>Equal opportunity to all. No discrimination. No harassment.</p>	Mitigation Implemented "Social Accountability Management System".	Negative
9	Corporate Governance (ESG)	Risk	<p>Business growth with an edge of ESG Compliance company from the customers and investors. Sustainable operations resulting in sustainable growth. ISO 14001:2015, ISO 45001:2018, ISO 50001:2018 and SA 8000:2014 Certifications for continual improvement in EHS performance. Non-compliance with the statutory requirements can adversely impact our operations, ability to raise funds from socially responsible investors and valuation of the Company.</p>	Mitigation Periodic risk assessments, internal audits and management reviews are conducted to ensure effective implementation of relevant management systems as part of corporate governance	Negative

SHILPA PHARMA LIFESCIENCES LIMITED

SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the National Guidelines on Responsible Business Conduct (NGRBC) Principles and Core Elements. Refer to the last page of this report for SDGs Mapping Against NGRBC.

Disclosure Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
Policy and management processes									
1. a. Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No)					Yes				
b. Has the policy been approved by the Board? (Yes/No)					Yes				
c. Web Link of the Policies, if available									https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility2.pdf
2. Whether the entity has translated the policy into procedures. (Yes / No)					Yes, the company has Translated all the Policies into Procedures & The code of conduct and ethics and/or other policies have imbibes the above-mentioned principles and the company expects its stakeholders to adhere to the same in all their dealings. https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility2.pdf Refer page no 1-12				
3. Do the enlisted policies extend to your value chain partners? (Yes/No)					Yes, the company's code of Supplier Code conduct and ethics and/or other policies imbibes the above-mentioned principles and the company expects its stakeholders to adhere to the same in all their dealings. The Purchase order species that the vendor Requires to Comply with the Suppliers code of Conduct https://www.vbshilpa.com/pdf/SPL-Suppliers%20Code%20of%20Conduct1.pdf				

SHILPA PHARMA LIFESCIENCES LIMITED

Disclosure Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
4. Name of the national and international codes / certifications / labels / standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustee) standards (e.g. SA 8000, ISO 45001, BIS) adopted by your entity and mapped to each principle.									
	<ul style="list-style-type: none"> • ISO 45001: 2018–Occupational Health & Safety Management Systems https://www.vbshilpa.com/pdf/SPL%20-%20ISO%2045001%20-%202018.pdf • ISO 14001: 2015- Environmental Management systems https://www.vbshilpa.com/pdf/SPL%20-%20ISO%2014001%20-%202015.pdf • SA 8000: 2014 – Social Accountability Management Systems https://www.vbshilpa.com/pdf/SPL%20-%20SA%208000-2014.pdf 								
5. Specific commitments, goals and targets set by the entity with defined timelines, if any.	Refer link : KPI's & performance: https://www.vbshilpa.com/pdf/SPL%20-%20Key%20Performance%20Indicators1.pdf								
6. Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.	Refer Link : KPI's & performance : https://www.vbshilpa.com/pdf/SPL%20-%20Key%20Performance%20Indicators1.pdf								
Governance, leadership and oversight									
7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements (<i>entity has flexibility regarding the placement of this disclosure</i>) Statement by Managing Director Our company monitors and ensures that we adhere to Environmental, Social, and Governance (ESG) principles, a commitment that threads through our continuous innovation and efficiency enhancement journey, including BRSR is a strategic move towards measuring our preparedness to integrate ESG principles into our operational matrix seamlessly. Beyond a mere assessment tool, the BRSR fortifies our commitment to transparency, providing our stakeholders with an all-encompassing insight into our sustainability endeavours. We perceive this initiative as an optimum platform to underscore our relentless dedication to responsible and sustainable practices, affirming our conviction that progress must be charted with ethical integrity, social accountability, and environmental stewardship.									
8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).	Mr. Vishnukant C Bhutada, Managing Director of the company.								

SHILPA PHARMA LIFESCIENCES LIMITED

Disclosure Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
9. Does the entity have a specified Committee of the Board/Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.	Yes, Mr. Vishnukant C Bhutada Managing Director								

10. Details of Review of NGRBCs by the Company:																		
Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee									Frequency (Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance Above policies and follow up action	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	The companies code of Conduct, Ethics & other policies imbibe the above mentioned principles & the co expects its stake holders to adhere to the same in all their dealings. As a practice, policies of the Company are reviewed periodically or on need basis by the Department heads, business heads and the Directors of the company.								
Compliance non-compliances	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Half Yearly								
11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency.										Environmental Management Systems –ISO 14001:2015 https://www.vbshilpa.com/pdf/SPL%20-%20ISO%2014001%20-%202015%20Report1.pdf Occupational Health & Safety Management Systems-ISO 45001:2018 https://www.vbshilpa.com/pdf/SPL%20-%20ISO%2045001%20-%202018%20Report.pdf by AQC Middle east LLC an Independent Certification Body Accredited by IAS (International								

SHILPA PHARMA LIFESCIENCES LIMITED

	accreditation services) Social accountability management systems : SA 8000 : 2014 https://www.vbshilpa.com/pdf/SPL%20-%20SA%20-%208000%20Report.pdf
--	---

12. If answer to question (1) above is “No” i.e. not all Principles are covered by a policy, reasons to be stated: Not Applicable

SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

PRINCIPLE-1 Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

Essential Indicators:

1. Percentage coverage by training and awareness programs on any of the Principles during the financial year:

Segment	Total number of training and awareness programs held	Topics /principles covered under the training and its impact	%age of persons in respective category covered by the awareness programs
Board of Directors	12	Familiarization/ awareness program for the Board of Directors/ KMPs of the Company is done periodically as part of Board process covering various areas pertaining to the business, strategy, risks, operations, regulations, code of business conduct and ethics, economy and environmental, social and governance parameters. In addition, frequent updates are shared with all the Board members/ KMPs to apprise them of developments in the Company, key regulatory changes, risks, compliances and legal cases.	100
Key Managerial Personnel	12		100
Employees other than BOD and KMPs	108	Engineering, EHS, Social Accountability code of conducts, Ethics and governance	100

SHILPA PHARMA LIFESCIENCES LIMITED

Segment	Total number of training and awareness programs held	Topics /principles covered under the training and its impact	%age of persons in respective category covered by the awareness programs
Workers	74	Material Handling, EHS & ESG social accountability, Code of Conducts, Ethics, Governance	80

2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format.

A. Monetary

Particulars	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In INR)	Brief of the Case	Has an appeal been Preferred? (Yes/No)
Penalty/ Fine					
Settlement					
Compounding Fee			NIL		

B. Non-Monetary

Particulars	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Brief of the Case	Has an appeal been Preferred? (Yes/No)
Imprisonment				
Punishment			NIL	

3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.

Case Details	Name of the regulatory/ enforcement agencies/ judicial institutions
NA	NA

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy.-

Yes, the company has an anti-bribery and corruption policy which is part of "Code of Business Conduct & Ethics. The policy is in the below weblink:

<https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility2.pdf>

Refer page no 16-17

SHILPA PHARMA LIFESCIENCES LIMITED

5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:

	FY 22-23	FY 21-22
Directors	NIL	NIL
KMPs		
Employees		
Workers		

6. Details of complaints with regard to conflict of interest:

	FY 22-23		FY 21-22	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	0		0	
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	0		0	

7. Details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.

Not Applicable.

Leadership Indicators:

1. Awareness programs conducted for value chain partners on any of the Principles during the financial year:

Total number of awareness programs held	Topics / principles covered under the training	%age of value chain partners covered (by value of business done with such partners) under the awareness programs
1	<ul style="list-style-type: none"> • Honest & ethical conduct & fair dealing • Compliance with the law rules & regulations • Confidential information • Insider trading • Employment practices & non discrimination • Treatment of employee • Sexual harassment • Health & safety 	60% Value Chain partners were covered.

SHILPA PHARMA LIFESCIENCES LIMITED

Total number of awareness programs held	Topics / principles covered under the training	%age of value chain partners covered (by value of business done with such partners) under the awareness programs
	<ul style="list-style-type: none"> • Supply Chan management • Production quality compliance • Sales & marketing practices • Advertising sales & packing • Gifts, Gratitude's, Bribes & Kickbacks & anti money laundering • Conflict of interest • Related party transactions • Accurate retention of business records • Whistle blower policy & procedure • Dealing with media • Responding to government requests • Prohibition against company political contributions • Copyrighted works • Responsibility to ask questions • Procedure for reporting possible violations. 	

2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? **(Yes/No)** If yes, provide details of the same.
Yes, As per the procedure laid down in the company's act.

PRINCIPLE 2 Businesses should provide goods and services in a manner that is sustainable and safe.

Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

Category	FY 22-23	FY 21-22	Details of improvements in environmental and social impacts
R&D	20%	21%	R&D Investments are focused on process efficiencies, sustainable technologies and green chemistries development involving flow chemistry for reduction of the resources and wastes.
Capex	7.5%	9%	Invested on pollution control process & technologies, renewable energy, solar power, energy efficient technologies, energy conservation measures, process efficiency equipment to reduce the environmental footprint.

SHILPA PHARMA LIFESCIENCES LIMITED

2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)
Yes, Refer web link
<https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility2.pdf>
- b. If yes, what percentage of inputs were sourced sustainably?
Yes, about 60% of the materials are sourced sustainably.
3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for
- (a) Plastics (including packaging)
The company is registered with Extended Producers responsibility with Central Pollution Control Board to recycle the plastic waste. Registration No.: 2023102006544845979
The company products are used by the customers for manufacturing, the packaging materials disposal of the used / received in the customers premises is disposed as per their hazardous waste authorization.
Any materials rejected is brought back to the factory premises and the plastic is disposed as per the hazardous waste Authorization through State Pollution Control Board (SPCB) authorized recyclers. The plastic waste disposed to authorized vendor.
- (b) E-waste
The company is not involved in sale of electronic goods, the small quantity of E-waste generated is disposed to Recyclers Authorized by Karnataka State Pollution control Board.
- (c) Hazardous waste
The products manufactured & sold by our company are used by customers for the manufacture of finished formulations, which are used by patients as per Doctor's advice. The plastic materials quantity dispatched in the market are compensated through the Plastic Recyclers by purchasing credits under Extended producers Responsibility
The Hazardous waste generated as part of manufacturing is safely disposed as per the Hazardous Waste Authorization given by KSPCB to the authorized personnel.
- (d) Other waste.
Other Non-Hazardous waste generated in house from Boiler like Boiler ash is safely disposed to the Brick manufacturers.
We have established relevant Policies and Procedures for safe storage and disposal of products at the end of life and environmentally sound waste recycling through authorized third parties as under:
- a) In FY2122, 87.2% of total wastes are recycled/reused through co-processing/ authorized agencies and 12.8% of total waste is disposed to secured landfill.
- b) In FY2223, 79.8% of total wastes are recycled/reused through co-processing/ authorized agencies and 20.1% of total waste is disposed to secured landfill.
- c) Boiler ash is disposed to brick manufacturers for usage in Construction industry & is Recycled 100% waste.

SHILPA PHARMA LIFESCIENCES LIMITED

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes/No).- If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.

Yes registered with central pollution control board. Registration No: 2023102006544845979. The collection plan is done through a registered recycler.

Leadership Indicators

1. Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? If yes, provide details in the following format?

NIC Code	Name of Product/Service	% of total Turnover contributed	Boundary for which the Life Cycle Perspective / Assessment was conducted	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No) If yes, provide the web-link.
210	Active Pharmaceuticals Ingredients	98%	Gate to Gate	No	No

2. If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same.

Name of Product / Service	Description of the risk / concern	Action Taken
Active Pharmaceutical Ingredients	Effluent from the Manufacturing Process is environmental Concern if Untreated	The effluent is Treated in The Zero Liquid Discharge system & The treated water is Recycled in Cooling Towers.
	Fire Hazard	The Company has Installed Full-fledged firefighting system comprising of Fire Hydrant, Foam, Fire extinguishers, Fire alarms, The Risk assessment is done & The suggested control Measures are in Place.
	Toxic Release	HIRA for all the activities & Hazop for all the products Manufacturing Process have been carried out & Necessary control Measures like scrubbers, Air Pollution Control measures are Installed.

SHILPA PHARMA LIFESCIENCES LIMITED

3. Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).

Indicate input material	Recycled or re-used input material to total material	
	FY 22-23	FY 21-22
Solvents	74%	75%

4. Of the products and packaging reclaimed at end of life of products, amount (in metric tons) reused, recycled, and safely disposed, as per the following format:

	FY 22-23			FY 21-22		
	Re-Used	Recycled	Safely Disposed	Re-Used	Recycled	Safely Disposed
Plastics (including packaging)	0	20 MT	NA	0	16MT	NA
E-waste	0	4.4MT(b Batteries)	Sold to Manufacturer on buy back	0	2.2MT(b Batteries)	Sold to Manufacturer on buy back
Hazardous waste	0	0	1553.39 MT	0	0	1259.09 MT
Other waste	2744 .76 MT boiler ash reused in construction bricks manufacturing	0	NA	2969.55 MT boiler ash reused in construction bricks manufacturing	0	NA

As our Company is engaged in the manufacturing of pharmaceutical products for human consumption, we do not reclaim products and packaging for reusing and recycling at the end of their life.

5. Reclaimed products and their packaging materials (as percentage of products sold) for each product category.

Indicate Product Category	Reclaimed products and their packaging materials as % of total products sold in respective category
Active Pharmaceutical Ingredients	The Rejected Materials are taken back to the factory, is investigated & reprocessed. The packaging materials are disposed to the Authorized Recyclers by Karnataka State Pollution Control Board. The packaging materials reclaiming is handled under extended producers responsibility through registered & authorized recyclers. The % of such product rejection is negligible (~0.0001%).

SHILPA PHARMA LIFESCIENCES LIMITED

PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in their value chains

1. a. Details of measures for the well-being of employees:

Category	% of employees covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B/A)	Number (C)	% (C/A)	Number (D)	% (D/A)	Number (E)	% (E/A)	Number (F)	% (F/A)
Permanent employees											
Male	1009	529	52%	1009	100%	0	0%	0	0%	0	0
Female	2	0	0	2	100%	0	0%	0	0%	0	0%
Total	1011	529	52%	1011	100%	0	0%	0	0%	0	0%
Other than Permanent employees											
Male	Not applicable										
Female											
Total											

b. Details of measures for the well-being of workers:

Category	% of workers covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B/A)	Number (C)	% (C/A)	Number (D)	% (D/A)	Number (E)	% (E/A)	Number (F)	% (F/A)
Permanent workers											
Male	207	166*	80,19%	207	100%	0	0	0	0	0	0
Female	0	0*	0%	0	0	0	0	0	0	0	0
Total	207	166	80.19%	207	100%	0	0	0	0	0	0
Other than Permanent workers											
Male	419	419	100%	419	100%	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0
Total	419	419	100%	419	100%	0	0	0	0	0	0

SHILPA PHARMA LIFESCIENCES LIMITED

2. Details of retirement benefits, for Current FY and Previous Financial Year.

Benefits	FY 22-23			FY 21-22		
	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the Authority (Y/N/N.A.)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)
PF	100%	100%	Yes	100%	100%	Yes
Gratuity	100%	100%	Yes	100%	100%	Yes
ESI	100%	100%	Yes	100%	100%	Yes
Others – please specify						

3. Accessibility of workplaces

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.

Yes, all the Buildings / Facilities in the premises are accessible to the differently abled employees except the manufacturing Areas where there is Requirement of quick evacuation during the emergencies and the differently abled personnel are not allowed to work in the manufacturing areas for safety reasons.

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.

Yes, Covered in code of conduct.- Refer Link

<https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility2.pdf>

5. Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender	Permanent employees		Permanent workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	0	NA	0	NA
Female	0	NA	0	NA
Total	0	NA	0	NA

SHILPA PHARMA LIFESCIENCES LIMITED

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If yes, give details of the mechanism in brief.

	Yes/No <i>(If Yes, then give details of the mechanism in brief)-</i>
Permanent Workers	Yes The Grievance redressal procedure Implemented and procedure is available at the link given here . The Policy provides avenues to report concerns directly to the compliance team. Code of Business Conduct and Ethics link: https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility2.pdf Refer Page No 80-85
Other than Permanent Workers	
Permanent Employees	
Other than Permanent Employees	

7. Membership of employees and worker in association(s) or Unions recognized by the entity:

Category	FY 22-23			FY 21-22		
	Total employees / workers in respective category (A)	No. of employees /workers in Respective category, who are part of association(s) or Union (B)	% (B/A)	Total employees / workers in respective category(C)	No. of employees / workers in respective category, who are part of association(s) or Union (D)	% (D/C)
Total Permanent Employees						
Male	1009	85	8.42	1003	85	8.47
Female	2	0	0	0	0	0
Total Permanent Workers						
Male	207	200	94.33	207	200	96.15
Female	0	0	0	0	0	0

SHILPA PHARMA LIFESCIENCES LIMITED

8. Details of training given to employees and workers:

Category	FY22-23					FY-21-22				
	Total (A)	On Health And safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		No. (B)	% (B/A)	No. (C)	% C/A)		No. (E)	%(E/D)	No. (F)	%(F/D)
Employees										
Male	1009	1009	100	1009	100	1003	1003	100	1003	100
Female	2	2	100	2	100	2	2	100	2	100
Total	1011	1011	100	1011	100	1005	1005	100	1005	100
Workers										
Male	207	207	100	207	100	207	207	100	207	100
Female	NA									
Total	207	207	100	207	100	207	207	100	207	100

9. Details of performance and career development reviews of employees and worker:

Category	FY22-23			FY 21-22		
	Total (A)	No. (B)	% (B / A)	Total (C)	No. (D)	%(D / C)
Employees						
Male	1009	950*	94.15%	1003	944*	94.11%
Female	2	2	100%	2	2	100%
Total	1011	952	94.16%	1005	946	94.12%
Workers						
Male	207	207	100%	207	207	100%
Female	0	0	0	0	0	0
Total	207	207	100%	207	207	100%

*The company evaluates the performance of the employees every year, out of 1009 Employees 59 people have not completed one year of service so these 59 employees PE is due in next financial year.

SHILPA PHARMA LIFESCIENCES LIMITED

10. Health and safety management system:

- a) Whether an occupational health and safety management system has been implemented by the entity? **(Yes/ No)**. If yes, the coverage such system?

Yes, All the units have implemented the Occupational Health & Safety Management Systems.

- b) What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

This is covered under the SOP No: SOP/U-2/EHS/GEN/023/01 Hazard identification and risk assessment & Environment aspects (HIRA) & refer link

<https://www.vbshilpa.com/pdf/SPL%20-%20Aspects-Hazards%20Identifaction%20And%20Evaluation.pdf>

HIRA – AO Block: <https://www.vbshilpa.com/pdf/SPL%20-%20HIRA%20AO%20BLOCK.pdf>

HIRA- EIA – Plant Summary:

<https://www.vbshilpa.com/pdf/SPL%20-%20HIRA%20&%20EIA%20Summary%20%20of%20plant.pdf>

- c) Whether you have processes for workers to report the work related hazards and to remove themselves from such risks. (Y/N)

This is covered under at safe behavior SOP No: SOP/U-2/EHS/GEN/015/06

<https://www.vbshilpa.com/pdf/SPL%20-%20SOP-U2-EHS-GEN-015-05.pdf>

Yes, This is covered under at safe behavior SOP No: Un safe acts & un safe condition & Near Misses are daily reported & and the major incidents are investigated and route cause analysis done and CAPA implemented.

Refer link

Incident Investigation Report

<https://www.vbshilpa.com/pdf/SPL%20-%20Incident%20Investigation%20Report.pdf>

Daily Safety Dash board:

<https://www.vbshilpa.com/pdf/SPL%20-%20Daily%20Safety%20Dashboard%20Report%2030-11-23.pdf>

Incident Accident Summary:

<https://www.vbshilpa.com/pdf/SPL%20-%20Incident%20Accident%20Summary.pdf>

- d) Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? **(Yes/ No** Yes, all our sites are having occupational Health Centre, which provides healthcare services for both occupational and non-occupational medical needs)

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category	FY 22-23	FY 21-22
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	0.323	0.0
	Workers	0.0	2.42
	Combined	0.249	0.535
Total recordable work-related injuries	Employees	14	3
	Workers	16	7
No. of fatalities	Employees	0	0
	Workers	0	0
High consequence work-related injury or ill-health (excluding fatalities)	Employees	1	0
	Workers	0	2

SHILPA PHARMA LIFESCIENCES LIMITED

12. Describe the measures taken by the entity to ensure a safe and healthy work place.

The company has a industrial hygiene procedures & assess the work place monitoring for VOC, LAL, API in Effluent, Environment, Dust & Indoor air quality testing for particulate matter at the dust generation areas like solid charging, milling sieving & packing operations. The company has SOPS refer SOP List in web link for ensuring the safe and healthy workplace & the data is monitored and reviewed and CAPA implemented.

EHS SOP List: <https://www.vbshilpa.com/pdf/SPL%20-%20SOP%20INDEX.pdf>

Industrial Hygiene Program report:

<https://www.vbshilpa.com/pdf/SPL-Industrial%20Hygiene%20Program%20Recomemdatations%20Review%20Report.pdf>

Protocol for VOC & LEL:

<https://vbshilpa.com/pdf/SPL%20-%20Protocol%20for%20VOC%20&%20LEL%20Monitoring%20.pdf>

Report VOC & LEL: <https://www.vbshilpa.com/pdf/SPL%20-%20Report%20VOC%20&%20LEL.pdf>

Suppliers Environment & Social Assessment Report:

<https://www.vbshilpa.com/pdf/SPL-SUP-SAQ-OFI-CAPA.pdf>

13. Number of Complaints on the following made by employees and workers:

	FY22-23			FY21-22		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	0	0	--	0	0	--
Health & Safety	38	0	--	32	0	--

Refer the minutes of the safety committee meeting at the link: Safety Committee Minutes & Compliance for 22-23

Safety committee meeting 11-12-23

<https://www.vbshilpa.com/pdf/SPL%20-%20Safety%20Committee%20Meeting%2011-12-2023.pdf>

14. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	100
Working Conditions	100

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.

Safety related incidents are reported and investigated by trained employees following root cause analysis (RCA) method to find out the root /most probable cause(s) for such incidents. CAPAs are proposed based RCA

SHILPA PHARMA LIFESCIENCES LIMITED

findings, which are monitored for implementation. Refer Link for near miss & incident investigation reports & their CAPA implementation.- Link the investigation reports & CAPA of near miss.

<https://www.vbshilpa.com/pdf/SPL%20-%20Incident%20Investigation%20Report.pdf>

Leadership Indicators:

1. **Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees (Y/N) (B) Workers (Y/N).** Yes, For Employees & Workers are covered with personal accident policy.

2. **Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.**

The company verifies the supplier's payments of statutory dues to the Govt. authorities in respect of Employee Provident Fund, Employee state Insurance every month and the PO clearly states that non compliances will lead to the termination of orders/contract

3. **Provide the number of employees / workers having suffered high consequence work- related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:**

Particulars	Total no. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 22-23	FY 21-22	FY 22-23	FY 21-22
Employees	NIL	NIL	NA	NA
Workers	NIL	NIL	NA	NA

4. **Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No)**

NO

5. **Details on assessment of value chain partners:**

Particulars	% of value chain partners (by value of business done with such partners) that were assessed
Health and safety practices	50
Working Conditions	50

SHILPA PHARMA LIFESCIENCES LIMITED

6. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners

Yes, CAPA compliance communicated and attached refer link.- CAPA Report & Communication

Suppliers Environment & Social Assessment Report:

<https://www.vbshilpa.com/pdf/SPL-SUP-SAQ-OFI-CAPA.pdf>

PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders.

Essential Indicators:

1. Describe the processes for identifying key stakeholder groups of the entity.

Our purpose of ‘Innovating for affordable healthcare’ encompasses all our stakeholders, because we consider our stakeholders as important partners in our journey to achieve our purpose. We have established relevant policy and procedure for stakeholder engagement, which helps us enhance our strategy development and decision-making. We engage on issues that are important to us as a business as well as to the stakeholders, with the objective of addressing their needs and expectations and identifying new opportunities to create value.

Our process of identification and classification of the stakeholders is defined by their interest, impact and participation in operations of the Company and engagement on various environmental, social and governance matters. Delivering on stakeholder needs expectations are integral part of our business. We listen to our stakeholders and have established various channel of communication, consultation and participation.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Stakeholders	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Employees	No	<ul style="list-style-type: none"> • Communication from Senior Management. • Communication through Emails. • Safety meetings, Canteen committee 	Continuous	1. Employee engagement, operational efficiencies, improvement opportunities, long-term strategy plans, training and awareness on safety/behavioural safety, motivation, personality

SHILPA PHARMA LIFESCIENCES LIMITED

Stakeholders	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
		<p>meetings</p> <ul style="list-style-type: none"> • Feedback, Suggestion Box, Toolbox meetings • Celebrations of Independence Day, Republic Day, Safety Week, World Environment Day. • Review meetings, Notice Boards. • Reward & Recognition programs, Spot award programs, cultural Programs. • Trainings, Get together, Appreciation meetings, Daily, Monthly review meetings; Employees Union meetings, Exit Suggestions in sealed covers, Risk assessment activities HIRA, EAIA, HAZOP 		<p>development, on job & classroom trainings; innovations, sharing of knowledge, learning</p> <p>2. Performance, training and career development reviews.</p> <p>3. Seeking feedback on work culture.</p> <p>4. Building a safe, diverse and inclusive work environment.</p>
Communities	No	Our engagement with the community Includes physical	Frequent and need based	Understanding the social /developmental

SHILPA PHARMA LIFESCIENCES LIMITED

Stakeholders	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
		visits as well as digital channels.		challenges of the communities. Developing sustainable ecosystems for our communities.
Government and Regulatory authorities	No	Our interactions with authorities take place through e-mails, meetings, submissions, etc. as required	Need-based	Our engagement with official authorities is multi-fold. With regulatory authorities, our engagement is aimed at discharging responsibilities and furthering our core business of product development, launch, manufacturing, etc. in keeping with the latest and highest standards of compliance. With policymakers, our engagement aims to understand and discuss matters pertaining to the industry.
Suppliers	No	Suppliers ESG assessments, Trade fairs, Exhibitions, Plant visits, Seminars, Professional networks, Vendor audits, Supply chain initiatives	1. Annual 2. Need based	Making a holistic impact on the health of patients worldwide requires us to work with partners across the healthcare value chain. We emphasize fair, transparent, and ethical practices and seek partners who share the same commitment towards compliance with laws, regulations, published standards and

SHILPA PHARMA LIFESCIENCES LIMITED

Stakeholders	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Customer	No	Website, Email, Trade Fairs (National & International), Customer Meetings, Customer Site Visits, Customer Audits for ESG, BD Team Interactions with Customers, VCs with Customers.	On-going	<p>environmental practices</p> <p>Ensure business continuity and opportunities without any environmental and social challenges.</p> <p>Seek confirmation on compliance with customer audit CAPAs.</p> <p>Understand customer's expectations on ESG and sustainable procurement and presenting same to the Board.</p> <p>Address any customer feedback/query on ESG and sustainable procurement.</p> <p>Response to customer needs, Customer audits & compliance of Audit points, Climate change disclosures, ESG compliance, Life cycle assessment.</p>

Leadership Indicators:

1. Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.

Respective business heads engage with the stakeholders on various ESG topics and the relevant feedback from such consultation is provided to the Board, wherever applicable.

SHILPA PHARMA LIFESCIENCES LIMITED

2. **Whether stakeholder consultation is used to support the identification and management of environmental, and social topics (Yes / No).**

If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.

Yes, our material issues are identified based on our stakeholder engagement process. Our Sustainability Goals (KPI's) are aligned to the operating context and its impact on various environmental and social aspects. – Refer Link

KPI Performance:

<https://www.vbshilpa.com/pdf/SPL%20-%20Key%20Performance%20Indicators1.pdf>

We have set our aspirations for sustainable growth by setting the sustainability goals as under:

- a) Ensuring Well-being of our Employees and Visitors including customers, contractors, sub-contractors.
- b) Working towards Carbon Neutrality.
- c) Working towards Water Neutrality.
- d) Working to achieving Zero Waste to Landfill.
- e) Promoting Green Chemistry & Green Engineering.

3. **Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.**

We engage with various stakeholders who may be classified as vulnerable/marginalized stakeholder groups. There are no reportable concerns of vulnerable / marginalized groups. However, the Company undertakes various CSR activities in nearby localities where our operational sites are located that serve the concerns of the vulnerable / marginalized stakeholder groups.

PRINCIPLE 5 Businesses should respect and promote human rights

Essential Indicators:

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

Category	FY22-23			FY 21-22		
	Total (A)	No. of employees / workers covered (B)	% (B / A)	Total (C)	No. of employees / workers covered (D)	% (D / C)
Employees						
Permanent	1011	1011	100%	1005	1005	100%
Other than permanent	0	0				
Total Employees	1011	1011	100%	1005	1005	100%

SHILPA PHARMA LIFESCIENCES LIMITED

Category	FY22-23			FY 21-22		
	Total (A)	No. of employees / workers covered (B)	% (B / A)	Total (C)	No. of employees / workers covered (D)	% (D / C)
Workers						
Permanent	207	207	100%	207	207	100%
Other than permanent	419	310	73.98%	385	285	66.23%
Total Workers	626	517	82.58	592	492	83.10

2. Details of minimum wages paid to employees and workers, in the following format:

Category	FY 22-23					FY 21-22				
	Total (A)	Equal minimum wage	to	More than Minimum Wage		Total (D)	Equal Minimum Wage	to	More than Minimum Wage	
		No. (B)	% (B/A)	No.(C)	% (C/A)		No. (E)	% (E/D)	No. (F)	% (F/D)
Employees										
Permanent										
Male	1009	0	0	1009	100%	1003	0	0	1003	100%
Female	2	0	0	2	100%	2	0	0	2	100%
Other than Permanent										
Male										
Female										
Workers										
Permanent										
Male	207	0	0	207	100%	207	0	0	207	100%
Female	0	0	0	0	0	0	0	0	0	0
Other than Permanent										
Male	419	419	100%	0	0	385	385	100%	0	0
Female										

SHILPA PHARMA LIFESCIENCES LIMITED

3. Details of remuneration/salary/wages, in the following format:

	Male		Female	
	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration / salary/ wages of respective category
Board of Directors (BoD)	4	INR 2.81 Million for the year 22-23	1	NA
Key Managerial Personnel	1	NA	1	NA
Employees other than BoD and KMP	1009	INR 1.91 Million for the year 22-23	2	INR 2.15 Million for the year 22-23
Workers	207	INR 1.06 Million for the Year 22-23	0	NA

4. **Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)**

Social Performance Team formed to address the Human Rights impacts or issues caused or contributed to by Business – Social Performance team Refer Link

<https://www.vbshilpa.com/pdf/SPL-Social%20Performance%20Team.pdf>

5. **Describe the internal mechanisms in place to redress grievances related to human rights issues. Grievance Redressal Procedure available – Refer Grievances Link**

<https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility2.pdf>

Refer Page No : 80-85

6. Number of Complaints on the following made by employees and workers:

	FY 22-23			FY 21-22		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	0	0		0	0	
Discrimination at workplace	0	0		0	0	
Child Labour	0	0		0	0	
Forced Labour/ Involuntary Labour	0	0		0	0	
Wages	0	0		0	0	
Other human rights related issues	NA					

SHILPA PHARMA LIFESCIENCES LIMITED

Mechanism of of Complaints Receiving at Mail ID [-info@vbsilpa.com](mailto:info@vbsilpa.com) , proof of Communication:

Refer Link – Mail From Head office

<https://www.vbsilpa.com/pdf/SPL%20-%20Complaints%20Mail%20Copy%20Report.pdf>

7. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

Discrimination has no place within our organization, and we maintain a zero-tolerance policy towards all forms of discrimination, including sexual discrimination. We actively encourage employees, contractors, and suppliers to report any instances of discrimination they witness. We promptly and effectively address these reports, ensuring that appropriate action is taken.

8. Do human rights requirements form part of your business agreements and contracts?

(Yes/No)

YES

9. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100%
Forced/involuntary labour	
Sexual harassment	
Discrimination at workplace	
Wages	
Others – please specify	NA

10. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 9 above.

During the assessment, no significant risks/concerns identified.

Leadership Indicators:

1. Details of a business process being modified / introduced as a result of addressing human rights grievances/complaints.
 - a. Grievance redressal committee formed
 - b. The summary of the complaints is maintained
 - c. Ensure the protection of complainant
 - d. Counselling & training to the complainant & harasser
 - e. Fair & Fine investigations & timely resolutions.
 - f. Disciplinary actions if required implemented on the harasser
 - g. Training to all the employees on grievances & Complainant.

SHILPA PHARMA LIFESCIENCES LIMITED

- Details of the scope and coverage of any Human rights due-diligence conducted.
Human Rights due- diligence not conducted.
- Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?
Yes
- Details on assessment of value chain partners:

	% of value chain partners (by value of business done with such partners) that were assessed
Sexual Harassment	50% of the suppliers who has submitted the SAQ duly filled in
Discrimination at workplace	
Child Labour	
Forced Labour / Involuntary Labour	
Wages	
Others – please specify	--

- Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above.

Refer the Link: <https://www.vbshilpa.com/pdf/SPL-SUP-SAQ-OFI-CAPA.pdf>

PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment.

Essential Indicators:

- Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:

Parameter	FY 2022-23 (GJ)	FY 2021-22 (GJ)
Total electricity consumption (A)- GJ	103780.3	97665.9
Total fuel consumption (B)- GJ	287706.05	305587.74
Energy consumption through other sources (C)-GJ	-	-
Total energy consumption (A+B+C) -GJ	391486.4	403253.6
Energy intensity per lakh of rupee of turnover (Total energy consumption/ turnover in rupees)	4.51	4.58
Energy intensity per Kg of Product (optional) – the relevant metric may be selected by the entity	0.16	0.14

SHILPA PHARMA LIFESCIENCES LIMITED

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No

2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any.

No

3. Provide details of the following disclosures related to water, in the following format:

Parameter	FY 22-23	FY 21-22
Water withdrawal by source (in kiloliters)		
(i) Surface water	64106.26	71786.0
(ii) Groundwater	-	-
(iii) Third party water	-	-
(iv) Seawater / desalinated water	-	-
(v) Others	-	-
Total volume of water withdrawal (in kiloliters) (i + ii + iii + iv + v)	64106.26	71786.0
Total volume of water consumption (in kiloliters)	64106.26	71786.0
Water intensity per lakh of rupees turnover (Water consumed / turnover)	0.7811	0.8696
Water intensity per Kg of Product (optional)–the relevant metric may be selected by the entity	0.0275	0.0272

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No

4. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

Yes, the Company has implemented a mechanism for zero liquid discharge (ZLD) at Unit-2 to cater for both for Unit 1 & Unit 2 (both API manufacturing sites located at Raichur, Karnataka). These units are in close proximity and is provided with a common ZLD facility, which is located at Unit 2. The unit recycles the whole Qty of treated water in utilities.

SHILPA PHARMA LIFESCIENCES LIMITED

5. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:

Parameter	Please specify unit	FY 22-23	FY 21-22
NOx	MT/A	9.2	9.11
SOx	MT/A	16.86	19.29
Particulate matter (PM)	MT/A	11.79	13.69
Persistent organic pollutants (POP)	NA	-	-
Volatile organic compounds (VOC)	MT/A	16.782	17.035
Hazardous air pollutants (HAP)	NA	-	-
Others please Specify (Acid Mist from Scrubber)	MT/A	3.89	2.6

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

Yes, the emission monitoring has been conducted by the MoEF & CC approved laboratory having accreditation from the National Accreditation Board for Testing and Calibration Laboratories. Refer Link MSV lab Reports :

<https://www.vbshilpa.com/pdf/SPL%20-%20MSV%20Report.pdf>

6. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:

Parameter	Unit	FY 22-23	FY 21-22
Total Scope 1 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tons of CO ₂ equivalent	3652.72	3900.12
Total Scope 2 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tons of CO ₂ equivalent	23638.84	22246.11
Total Scope 1 and Scope 2 emissions per lakh rupee of turnover	TCO ₂ e/ lakh	0.3325	0.3167
Total Scope 1 and Scope 2 emission intensity per Kg of Product (<i>optional</i>) – the relevant metric may be selected by the entity	TCO ₂ e/GJ	0.0117	0.0099

SHILPA PHARMA LIFESCIENCES LIMITED

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

NO

7. Does the entity have any project related to reducing Green House Gas emission? If Yes, then provide details.

Yes. In line with our goal of becoming 'Carbon Neutral by 2030', we work towards improving the energy conservation, energy efficiency, use of renewable energy and use of biofuels across operational locations by implementing several projects to enhance the proportion of renewable energy resources (electricity and biofuels) in our total energy mix and reduction of greenhouse gases (GHGs).

The Entity has Registered its Biomass Based Steam Generation project with UNFCCC Project No-3926 under the Kyoto Protocol and GHG Reduction by using Biomass fired steam generation with Coal as Base line in the Year 22-23 – 10.875tCO₂e & 21-22 -10.875 TCO₂ e : Refer Link : Biomass Based Steam Generation project – UNFCCC

<https://www.vbshilpa.com/pdf/CDM%20Biomass-based%20Steam%20generation%20project%20at%20SPL.pdf>

8. Provide details related to waste management by the entity, in the following format:

Parameter	FY 22-23	FY 21-22
Total Waste generated (in metric tons)		
Plastic waste (A)	16MT	16MT
E-waste (B)	-	-
Bio-medical waste (C)	-	-
Construction and demolition waste (D)	-	-
Battery waste (E)	4.4 MT	2.2 MT
Radioactive waste (F)	-	-
Other Hazardous waste. Please specify, if any. (G)	1635.36 MT	1275.09 MT
Other Non-hazardous waste generated (H) . Please specify, if any. (Break-up by composition i.e. by materials relevant to the sector)	2769.85 MT	2969.55 MT
Total (A+B + C + D + E + F + G+ H)	4429.61 MT	4262.84 MT
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tons)		
Category of waste		
(i) Recycled	695.84	723.93
(ii) Re-used	2755.38	2978.09
(iii) Other recovery operations	-	-
Total	3451.22	3702.03
For each category of waste generated, total waste disposed by nature of disposal method (in metric tons)		

SHILPA PHARMA LIFESCIENCES LIMITED

Parameter	FY 22-23	FY 21-22
Category of waste		
(i) Incineration	-	-
(ii) Landfilling	876.35	540.51
(iii) Other disposal operations	-	-
Total	876.35	540.51

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

YES Karnataka State Pollution Control Board inspects the site & Monthly returns filing the data of hazardous wastes disposed & Is Reviewed by the Pollution Control Board.

9. **Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.**

Shilpa has consistently scaled up its waste management practices by reducing waste quantities & Reducing the resources & minimizing the Hazards by adopting the green Chemistry & green technologies like Flow & Continuous flow technologies , the company has invested in advanced technologies to develop & adopt the flow technology to reduce the hazards & Risks The Company adopts environmentally sound disposal of Combustible waste to Co- Processing & Other wastes for reuse & recycling & a small portion of the waste is only sent to authorized Treatment, Storage and Disposal Facilities (TSDF). We are increasing the share of recycling and co-processing to bring down the quantity of waste disposed to landfills.

We have dedicated storage area for different type of waste (hazardous, biomedical, e-waste, and non-hazardous) and waste segregation is done at source.

All types of wastes are labelled, stored and disposed as per applicable rules and consent to operate. The Non Hazardous waste is disposed to Brick Manufacturing industries & is 100% Reused - Boiler Ash.

10. **If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:**

S.No.	Location of operations/offices	Type of Operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and Corrective action taken, if any.
Not applicable			

SHILPA PHARMA LIFESCIENCES LIMITED

11. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

Not applicable

12. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

Yes.

S. No.	Specify the law / regulation/ guidelines which was not complied with	Provide Details of The non-compliance	Any fines/ penalties/action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
Not applicable				

Leadership Indicators:

1. Provide break-up of the total energy consumed (in Joules or multiples) from renewable and non-renewable sources, in the following format:

Parameter	FY 22-23	FY 21-22
From renewable sources		
Total electricity consumption (A)- GJ	72648	82143.2
Total fuel consumption (B) -GJ	255765.02	272542.57
Energy consumption through other sources (C)	-	-
Total energy consumed from renewable sources (A+B+C)	328413.02	354685.77
From non-renewable sources		
Total electricity consumption(D)	31132.3	15522.7
Total fuel consumption (E)	31941.02	33045.18
Energy consumption through other sources (F)	-	-
Total energy consumed from non-renewable sources (D+E+F)	63073.32	48567.88

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

YES

GESCOM (Gulbarga Electricity Supply Company- a Karnataka State Owned Electricity supply Company) verifies every month & issues the office memorandum for wheeling of units Generated

SHILPA PHARMA LIFESCIENCES LIMITED

by the parent company – Shilpa Medicare Ltd & Wind power purchased from Atria - Refer Link For Office memorandum issued by GESCOM

Renewable energy verification NOV 23 OM:

https://www.vbshilpa.com/pdf/SPL%20-%20Shilpa%20Medicare%20Nov_2023.pdf

Renewable energy verification NOV 23

https://www.vbshilpa.com/pdf/SPL%20-%20Atria%20Wind_C%20Nov_2023%20OM.pdf

2. Provide the following details related to water discharged:

Parameter	FY 22-23	FY 21-22
Water discharge by destination and level of treatment (in kiloliters)		
(i) To Surface water	-	-
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(ii) To Groundwater	-	-
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(iii) To Seawater	-	-
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(iv) Sent to third-parties	-	-
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(v) Others	Treated water Reused in cooling towers	Treated water Reused in cooling towers
- No treatment	-	-
- With treatment – please specify level of treatment	Up to Tertiary Treatment & Reduce the COD less than -250PPm	Up to Tertiary Treatment & Reduce the COD less than -250PPm
Total water discharged (in kiloliters)	44089KL	55933 KL

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

NO

SHILPA PHARMA LIFESCIENCES LIMITED

3. Water withdrawal, consumption and discharge in areas of water stress (in kiloliters):
For each facility / plant located in areas of water stress, provide the following information:
- (i) Name of the area: Deosugur/Chicksugur, Raichur
 - (ii) Nature of operations: Manufacturing
 - (iii) Water withdrawal, consumption and discharge in the following format:

Parameter	FY 22-23	FY 21-22
Water withdrawal by source (in kiloliters)		
(i) Surface water	64106.26	71786.00
(ii) Groundwater	-	-
(iii) Third party water	-	-
(iv) Seawater / desalinated water	-	-
(v) Others	-	-
Total volume of water withdrawal (in kiloliters)	64106.26	71786.00
Total volume of water consumption (in kiloliters)	64106.26	71786.00
Water intensity per lakh of rupee of turnover (<i>Water consumed / turnover</i>)	0.7811	0.8696
Water intensity per Kg of Product (<i>optional</i>) – the relevant metric may be selected by the entity	0.252	0.259
Water discharge by destination and level of treatment (in kiloliters)		
(i) Into Surface water		
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(ii) Into Groundwater		
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(iii) Into Seawater		
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(iv) Sent to third-parties		
- No treatment	-	-
- With treatment – please specify level of treatment	-	-
(v) Others	Treated water Reused in cooling towers	Treated water Reused in cooling towers

SHILPA PHARMA LIFESCIENCES LIMITED

Parameter	FY 22-23	FY 21-22
- No treatment	-	-
- With treatment – please specify level of treatment	Up to Tertiary Treatment & Reduce the COD less than - 250PPm	Up to Tertiary Treatment & Reduce the COD less than - 250PPm
Total water discharged (in kiloliters)	44089 KL	55933 KL

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

NO

4. Please provide details of total Scope 3 emissions & its intensity, in the following format:

Parameter	Unit	FY 22-23	FY 21-22
Total Scope 3 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tons of CO ₂ equivalent	710.41	877.77
Total Scope 3 emissions per lakh rupee of turnover	TCO ₂ e/ lakh	0.87	1.06
Total Scope 3 emission intensity per Kg of Product (<i>optional</i>) – the relevant metric may be selected by the entity		NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No

5. With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities.

The Company is located at the Govt. Notified Industrial Area & Hence no impact on Biodiversity.

SHILPA PHARMA LIFESCIENCES LIMITED

6. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:

The following Water consumption reduction programs is implemented.

S. No	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
1	Controlling API in Effluent	<p>API Content in effluent procedure: https://www.vbshilpa.com/pdf/SPL%20-%20API%20Content%20in%20Effluent%20Procedure.pdf</p> <p>API Content in effluent Report: https://www.vbshilpa.com/pdf/SPL%20-%20API%20Content%20in%20Effluent%20Report.pdf</p>	The treated water does not contain any API and the treated water is free from contamination.
1	Water Reduction	In the Purified water generation system the Rejects from Electrodialyser, Reverse osmosis Reject & Pretreatment & Ultrafiltration Back flush/ Fast Flush are Recycled to Reduce the water consumption	36000 KL of water is Recycled from the water treatment & hence is conserved in 22-23, The
2	Steam Economy Improvement- Thermal Energy Conservation	Steam economy improved by installing the additional effect in the MEE there by Conserving the energy	A thermal Energy of 4166Million Kcal is Conserved in this Operation
3	Reduction of Rejects from Reverse Osmosis	The company has installed a Reverse osmosis system to Treat the RO Rejects, there by reducing the Ro Reject volume to 50% to be evaporated & Condensed	5129 Million Kcal Thermal energy is Conserved

7. Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link.

YES – Refer Web Link for Business Continuity plan.

<https://www.vbshilpa.com/pdf/SPL%20-%20BCP%20Procedure.pdf>

8. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard.

No Significant adverse impact on the environment from Value Chain activity of the company. Hence, mitigation measures are Not applicable

9. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

50% of the Supplier assessment questionnaire duly filled & Received back from the vendor.

SHILPA PHARMA LIFESCIENCES LIMITED

PRINCIPLE 7 Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent.

Essential Indicators:

1. a. Number of affiliations with trade and industry chambers/ associations.
- b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to.

S. No.	Name of the trade and industry chambers/associations	Reach of trade and industry chambers/ associations (State/National)
1.	Raichur chamber of Commerce & Industry	State- Karnataka
2.	Pharmexil- Hyderabad	National- India
3.	Raichur Chemical Manufacturers Association	State- Karnataka
4.	Export Promotion Council for EOU/SEZ	National - India

2. Provide details of corrective action taken or underway on any issues related to anti- competitive conduct by the entity, based on adverse orders from regulatory authorities.

No Issue on anti competitive practices by the company, Hence no adverse actions by the regulatory

Name of authority	Brief of the case	Corrective action taken
NA	NA	NA

Leadership Indicators:

S. No.	Public policy Advocated	Method resorted for such advocacy	Whether information available in public Domain? (Yes/No)	Frequency of Review by Board (Annually/Half yearly/Quarterly /Others Please specify)	Web Link, If available
1	The formulated policies in line with the Regulatory Requirements & UNGC are available for Public on the company website	Company web site for Policies and Management systems PO – suppliers Code of Conduct BRSR – Available on web site	YES available on Companies web site	Annually	Refer – Link https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility%202.pdf

SHILPA PHARMA LIFESCIENCES LIMITED

PRINCIPLE 8 Businesses should promote inclusive growth and equitable development

Essential Indicators:

1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.
No Significant Projects / Expansion done by the entity in the last two years.

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:
No

3. Describe the mechanisms to receive and redress grievances of the community.
Most of the activities are carried out in discussion and agreement with the community members. In case of any grievances, the community leaders can reach out to the Company's point of contact (POC) at each of the units. The POC is directly and easily accessible to the community to address any concerns that may arise. Depending on the nature of complaint, relevant stakeholders are engaged to resolve any issue.

Refer the link Grievance redressal Procedure :

<https://www.vbshilpa.com/pdf/SPL%20-%20Corporate%20Social%20Responsibility2.pdf>

Refer the Page No: 80- 85

Percentage of input material (inputs to total inputs by value) sourced from suppliers:

	FY 22-23	FY 21-22
Directly sourced from MSMEs/ small producers	79%	77%
Sourced directly from within the district and neighboring districts	3%	2.5

Leadership Indicators:

1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):
No Significant Negative impacts due to the Project, However the land looser have been provided with the employment

Details of negative social impact identified	Corrective action taken
Loss of employment by the land looser to the Govt. Notified Industrial area	The land looser pertaining to the land allotted to us have been provided with the employment

2. Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies: Currently not applicable.
3. (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No)
YES, The Supply chain Management system has a provision for procurement from Marginalized & Vulnerable groups in the diversity section

SHILPA PHARMA LIFESCIENCES LIMITED

(b) From which marginalized /vulnerable groups do you procure?

The Rice Husk which is used as a renewable fuel for steam Generation is Collected from the rice mills by the aged Dalit persons & Shilpa Collects Through the Raw Impex Get them Delivered

(c) What percentage of total procurement (by value) does it constitute?

3% of the total Value of the procurement is done

4. Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:
Not Applicable. The company is into Active Pharmaceutical Ingredients Manufacturing, Traditional Knowledge is not use.

S. No.	Intellectual Property based on traditional knowledge	Owned/ Acquired (Yes/No)	Benefit shared (Yes / No)	Basis of calculating benefit share
Not Applicable				

5. Details of corrective actions taken or underway based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.

Name of authority	Brief of the Case	Corrective action taken
Not Applicable		

6. Details of beneficiaries of CSR Projects: Currently not applicable.

PRINCIPLE 9 Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators:

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
We have Standard Operating Procedure (SOP) in Place to handle the consumer complaints and feedback. The complaints are received by email and reply after due investigation. Each complaint is logged in and evaluated and investigated from either a (i) Quality or a (ii) Safety or (iii) both perspectives. Complaint is closed after investigation and appropriate regulatory action has been taken.

Refer Link For SOP Handling of customer complaint Procedure:

<https://www.vbshilpa.com/pdf/Handling%20of%20Customer%20complaint.pdf>

2. Turnover of products and/ services as a percentage of turnover from all products/service that carry information about:

	As a percentage to total turnover
Environmental and social parameters relevant to the product	100%
Safe and responsible usage	100%
Recycling and/or safe disposal	100%

SHILPA PHARMA LIFESCIENCES LIMITED

3. Number of consumer complaints in respect of the following:

	FY 22-23 (Current Financial Year)		Remarks	FY21-23 (Previous Financial Year)		Remarks
	Received during the year	Pending resolution at end of year		Received during the year	Pending resolution at end of year	
Data privacy	NIL	NA	NA	NIL	NA	NA
Advertising						
Cyber-security						
Delivery of essential services						
Restrictive Trade Practices						
Unfair Trade Practices						
Other						

Details of instances of product recalls on account of safety issues:

	Number	Reasons for recall
Voluntary recalls	NIL	NA
Forced recalls	NIL	NA

Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No), If available, provide a web-link of the policy.

Yes, Company has a privacy policy for all its legal entities and business. This can be accessed on our website.

IT Policy Data privacy is covered IT policy Information Technology Policy:

<https://www.vbshilpa.com/pdf/SPL%20-%20IT%20Usage%20Policy.pdf>

Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.

NIL ; No issues on advertising, Cyber security , Data privacy instances of Product recalls , penalty & Hence No cation by Regulatory authorities on safety of products.

Leadership Indicators

1. Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available).

Refer web link.- For Products & Services

<https://www.vbshilpa.com/api-products.php>

SHILPA PHARMA LIFESCIENCES LIMITED


















2. Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.
Certificate of Analysis & SDS issued along with the Consignment to the customers (Formulation Manufacturers).
3. Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.
Information to the customer of any risk of disruption/discontinuation of the supplies covered as a part of the Drug master file as Commitment & also apart of the quality & supply agreement with the customer
SHILPA is being followed the procedure to notify the customers regarding of any risk of disruption/discontinuation of essential services. SHILPA will address the changes in change notification and same will be share to customers through E-mail.
SHILPA shall not make any changes that have an impact on regulatory submissions without written notification from customer that Regulatory Authority approval has been granted when necessary.
If any changes in existing, will notify Customers through in writing prior to any critical or major changes to materials, Components, facilities, testing, utilities, equipment, and processes that may impact the Product safety, integrity, identity, strength, purity, quality, and /or regulatory filing - prior to implementation of the changes.
Change notification shall be sent through email, as indicated in this document
4. Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable)
Not Applicable
If yes, provide details in brief. – NA
Did your entity carry out any survey with regard to consumer satisfaction relating to the major products / services of the entity?
The Customer satisfaction is obtained from the Customers by way of Customer audits & on satisfaction of the manufacturing systems & quality systems compliance the customer gives the report that the business can be continued for period specified in the report
Significant locations of operation of the entity or the entity as a whole? (Yes/No)
YES

Customer feedback report: Refer audit conclusions
<https://www.vbshilpa.com/pdf/SPL%20-%20Customer%20Feedback%C2%A0Report.pdf>
5. Provide the following information relating to data breaches:
 - a. Number of instances of data breaches along-with impact: No Data Breaches
 - b. Percentage of data breaches involving personally identifiable information of customers - 0%

SHILPA PHARMA LIFESCIENCES LIMITED

SDGs Mapping Against NGRBC

The chart demonstrates the alignment between the SDGs and relevant Principles of the NGRBC. It may be noted that this is indicative.

 <p>1 NO POVERTY</p>	P3, P4, P8	 <p>7 AFFORDABLE AND CLEAN ENERGY</p>	P2, P6, P7	 <p>13 CLIMATE ACTION</p>	P2, P6, P7, P8
 <p>2 ZERO HUNGER</p>	P2, P6, P7, P8, P9	 <p>8 DECENT WORK AND ECONOMIC GROWTH</p>	P2, P3, P5, P8	 <p>14 LIFE BELOW WATER</p>	P2, P6, P7, P8, P9
 <p>3 GOOD HEALTH AND WELL-BEING</p>	P3, P6, P8	 <p>9 INDUSTRY, INNOVATION AND INFRASTRUCTURE</p>	P3, P4, P8	 <p>15 LIFE ON LAND</p>	P2, P6, P7, P8, P9
 <p>4 QUALITY EDUCATION</p>	P3, P8, P9	 <p>10 REDUCED INEQUALITIES</p>	P2, P6, P7	 <p>16 PEACE, JUSTICE AND STRONG INSTITUTIONS</p>	P1, P3, P4, P5, P8
 <p>5 GENDER EQUALITY</p>	P3, P4, P5, P8	 <p>11 SUSTAINABLE CITIES AND COMMUNITIES</p>	P3, P4, P7, P8	 <p>17 PARTNERSHIPS FOR THE GOALS</p>	P1, P7, P8
 <p>6 CLEAN WATER AND SANITATION</p>	P2, P6, P8	 <p>12 RESPONSIBLE CONSUMPTION AND PRODUCTION</p>	P2, P6, P9		★

Ref: https://www.mca.gov.in/Ministry/pdf/NationalGuideline_15032019.pdf